Clinical trials: Covid19 Vaccination
COVID-19
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinical efficacy and safety of…
- Trial name
- NCT04521309
- Testing
- SARS-CoV-2 antibody based IVIG therapy
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Dow University of Health Sciences
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study.
- Trial name
- NCT05664932
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Covid19
The Impact of Vaccination on Severity of Illness in COVID-19
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus…
- Trial name
- NCT04912700
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 11,834 people
- Sponsor
- Corewell Health East
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine
COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health.
- Trial name
- NCT05373030
- Testing
- Recombinant adenovirus type-5-vectored COVID-19 vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695130
- Testing
- RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
SARS-CoV-2 Infection
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were…
- Trial name
- NCT05534035
- Testing
- PTX-COVID19-B, Vaxzevria®
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
SARS-COV 2, Covid19
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19
This is an open-label, two arm interventional exploratory study to evaluate the safety and efficacy of 5-ALA-Phosphate-SFC during the vaccination of subjects against SARS-CoV-2 (COVID-19) virus infection to define the safety and…
- Trial name
- NCT04854876
- Testing
- 5-ALA-Phosphate + SFC (5-ALA+SFC)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Kidney Failure, Chronic, Covid19
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
- Conditions
- Kidney Failure, Chronic, Covid19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- COViNEPH-1 (NCT04905862)
- Testing
- Immune response, Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
- Where
- 4 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Multisite Observational Maternal and Infant Study for COVID-19
This is an observational, non-interventional, prospective cohort study designed to collect clinical information and specimens to evaluate the immune responses from pregnant individuals and postpartum individuals and their infants…
- Trial name
- MOMI-Vax (NCT05031468)
- Testing
- Licensed or EUA SARS-CoV-2 vaccine
- Where
- 10 sites in United States
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Emory University
Vaccine Hesitancy
The Effect of Newspaper Reporting on COVID-19 Vaccine Hesitancy: a Randomised Controlled Trial
COVID-19 vaccine hesitancy can be observed at different rates in different countries. 1,068 people were surveyed in France and Italy to inquire about individual potential acceptance, focusing on time preferences, in a risk-return…
- Trial name
- COVANEW (NCT05582564)
- Testing
- abstract vs concrete texts
- Where
- Italy
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- University of Bari Aldo Moro
Covid19 Vaccine
Covid-19 Vaccine Response in Elderly Subjects
The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9…
- Trial name
- MONITOCOVAGING (NCT04760704)
- Testing
- Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration
- Where
- France
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
SARS-CoV-2
Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older
This is a multi-center, randomized, blinded, placebo-controlled, phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 bivalent mRNA vaccine (LVRNA021) as booster in participants aged 18 years…
- Trial name
- NCT05812014
- Testing
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution
- Where
- Pakistan
- Volunteers
- 9,800 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05033847
- Testing
- Recombinant COVID-19 Vaccine (CHO cell), COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19 Infection, Immunization; Infection
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
The goal of this observational study is to evaluate the protective effect of immune barrier on secondary infection after COVID-19 (coronavirus disease 2019) vaccination or COVID-19 virus Omicron B A.
- Trial name
- COVID (NCT05774093)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Multiple Sclerosis
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the…
- Trial name
- NCT05081271
- Testing
- Homologous booster, Heterologous booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Griffin Hospital
Covid19, Vaccines
Text-based Reminders to Promote COVID-19 Vaccinations
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine.
- Trial name
- NCT04801524
- Testing
- Self-benefit, Prosocial-benefit, Early access
- Where
- United States
- Volunteers
- 250,000 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline